Protein C

Identification

Name
Protein C
Accession Number
DB11312
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Blood factors
Description

Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Also known as blood coagulation factor XIV, Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation.

The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli. A lack of Protein C in the body would lead to unchecked coagulation activation, resulting in thrombin generation and intravascular clot formation with thrombosis.

Protein C is available in concentrated form as the product Ceptrotin, which is indicated foruse in pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.

Protein structure
Db11312
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • autoprothrombin IIA
  • blood coagulation factor XIV
  • Human protein C
  • Protein C (coagulation inhibitor)
  • Protein C concentrate
  • Protein C concentrate (human)
  • Protein C concentrate human
  • Protein C human
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CeprotinInjection, powder, for solution500 IUIntravenousBaxter Ag2001-07-16Not applicableEu
CeprotinKitBaxter Laboratories2010-08-09Not applicableUs
CeprotinKitBaxalta Canada Corporation2010-08-09Not applicableUs
CeprotinInjection, powder, for solution1000 IUIntravenousBaxter Ag2001-07-16Not applicableEu
CeprotinKitBaxalta Canada Corporation2010-08-09Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Beriplex P/n 1000Protein C (1640 unit) + Coagulation Factor IX Human (1240 unit) + Coagulation factor VII human (1000 unit) + Coagulation factor X human (2040 unit) + Protein S human (1360 unit) + Prothrombin (1600 unit)Powder, for solutionIntravenousCsl Behring2013-11-21Not applicableCanada
Beriplex P/n 500Protein C (820 unit) + Coagulation Factor IX Human (620 unit) + Coagulation factor VII human (500 unit) + Coagulation factor X human (1020 unit) + Protein S human (680 unit) + Prothrombin (800 unit)Powder, for solutionIntravenousCsl Behring2011-07-28Not applicableCanada
KcentraProtein C + Coagulation Factor IX Human + Coagulation factor VII human + Coagulation factor X human + Protein S human + Prothrombin + WaterKitCsl Behring2013-12-13Not applicableUs
KcentraProtein C + Coagulation Factor IX Human + Coagulation factor VII human + Coagulation factor X human + Protein S human + Prothrombin + WaterKitCsl Behring2013-04-29Not applicableUs
OctaplexProtein C (1240 unit) + Coagulation Factor IX Human (1000 unit) + Coagulation factor VII human (960 unit) + Coagulation factor X human (1200 unit) + Protein S human (1280 unit) + Prothrombin (1520 unit)Kit; Powder, for solutionIntravenousOctapharma Pharmazeutika Produktionsges M B H2015-08-11Not applicableCanada
OctaplexProtein C (620 unit) + Coagulation Factor IX Human (500 unit) + Coagulation factor VII human (480 unit) + Coagulation factor X human (600 unit) + Protein S human (640 unit) + Prothrombin (760 unit)Kit; Powder, for solutionIntravenousOctapharma Pharmazeutika Produktionsges M B H2008-07-08Not applicableCanada
Categories
UNII
3Z6S89TXPW
CAS number
Not Available

Pharmacology

Indication

Protein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.

Structured Indications
Not Available
Pharmacodynamics

In clinical studies, the intravenous administration of Protein C Concentrate demonstrated a temporary increase, within approximately half an hour of administration, in plasma levels of APC. Replacement of protein C in protein C-deficient patients is expected to control or, if given prophylactically, to prevent thrombotic complications [FDA Label].

Mechanism of action

Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Also known as blood coagulation factor XIV, Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). Once in its activated form, APC functions as a serine protease with potent anticoagulant effects, especially in the presence of its cofactor protein S. APC exerts its effect by inactivating essential components of the coagulation cascade (specifically factors V and VIII), which leads to a decrease in thrombin formation, and therefore a reduction in clot formation.

Absorption

Cmax = 110 IU/dL Tmax = 0.50 hr

Volume of distribution

Volume of distribution at steady state = 0.74 dL/kg

Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

Initial half life = 7.8 hr Terminal half life = 9.9 hr

Clearance

CL = 0.0533 dL/kg/h

Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Protein C.Investigational
AbciximabAbciximab may increase the anticoagulant activities of Protein C.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Protein C.Approved, Investigational
AcemetacinThe risk or severity of bleeding can be increased when Protein C is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Protein C.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Protein C.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Protein C.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Protein C.Approved, Withdrawn
AllylestrenolThe therapeutic efficacy of Protein C can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Protein C.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Protein C.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Protein C.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Protein C.Approved
AltrenogestThe therapeutic efficacy of Protein C can be decreased when used in combination with Altrenogest.Vet Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Protein C.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Protein C.Approved
AncrodAncrod may increase the anticoagulant activities of Protein C.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Protein C.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Protein C.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Protein C.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Protein C.Approved, Investigational
Antithrombin III humanProtein C may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Protein C.Approved
ApocyninApocynin may increase the anticoagulant activities of Protein C.Investigational
ApremilastApremilast may increase the anticoagulant activities of Protein C.Approved, Investigational
AprotininThe therapeutic efficacy of Protein C can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Protein C.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Protein C.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Protein C.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Protein C.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Protein C.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Protein C.Experimental
BecaplerminBecaplermin may increase the anticoagulant activities of Protein C.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Protein C.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Protein C.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Protein C.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Protein C.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Protein C.Approved
BeraprostBeraprost may increase the anticoagulant activities of Protein C.Investigational
BevoniumBevonium may increase the anticoagulant activities of Protein C.Experimental
BivalirudinBivalirudin may increase the anticoagulant activities of Protein C.Approved, Investigational
BrinaseBrinase may increase the anticoagulant activities of Protein C.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Protein C.Approved
BucillamineBucillamine may increase the anticoagulant activities of Protein C.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Protein C.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Protein C.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Protein C.Experimental
ButylphthalideButylphthalide may increase the anticoagulant activities of Protein C.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Protein C.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Protein C.Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Protein C.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Protein C.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Protein C.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Protein C.Approved, Investigational
CertoparinCertoparin may increase the anticoagulant activities of Protein C.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Protein C.Investigational, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Protein C.Approved
CilostazolCilostazol may increase the anticoagulant activities of Protein C.Approved, Investigational
Citric AcidCitric Acid may increase the anticoagulant activities of Protein C.Approved, Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Protein C.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Protein C.Approved
CloricromenCloricromen may increase the anticoagulant activities of Protein C.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Protein C.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Protein C is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Protein C.Approved
CurcuminCurcumin may increase the anticoagulant activities of Protein C.Approved, Investigational
Dabigatran etexilateProtein C may increase the anticoagulant activities of Dabigatran etexilate.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Protein C.Experimental
DalteparinDalteparin may increase the anticoagulant activities of Protein C.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Protein C.Approved, Withdrawn
DarexabanProtein C may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Protein C.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Protein C is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Protein C.Approved, Investigational
DemegestoneThe therapeutic efficacy of Protein C can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Protein C is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Protein C.Investigational
DesirudinDesirudin may increase the anticoagulant activities of Protein C.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Protein C.Investigational
DesogestrelThe therapeutic efficacy of Protein C can be decreased when used in combination with Desogestrel.Approved
DextranDextran may increase the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
Dextran 40Dextran 40 may increase the anticoagulant activities of Protein C.Approved
Dextran 70Dextran 70 may increase the anticoagulant activities of Protein C.Approved
Dextran 75Dextran 75 may increase the anticoagulant activities of Protein C.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Protein C.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Protein C.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Protein C.Approved, Investigational
DienogestThe therapeutic efficacy of Protein C can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Protein C.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Protein C.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Protein C.Approved, Investigational
DiphenadioneDiphenadione may increase the anticoagulant activities of Protein C.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Protein C.Approved
DitazoleDitazole may increase the anticoagulant activities of Protein C.Approved, Withdrawn
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Protein C.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Protein C.Investigational
DydrogesteroneThe therapeutic efficacy of Protein C can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Protein C.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Protein C.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Protein C.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Protein C.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Protein C.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Protein C.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Protein C.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Protein C.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Protein C.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Protein C.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Protein C.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Protein C.Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Protein C.Approved
EstroneEstrone may decrease the anticoagulant activities of Protein C.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Protein C.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Protein C.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Protein C.Approved
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Protein C.Withdrawn
EtodolacEtodolac may increase the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Protein C.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Protein C can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Protein C.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Protein C.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Protein C.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Protein C.Experimental
FenbufenFenbufen may increase the anticoagulant activities of Protein C.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Protein C.Approved
FentiazacFentiazac may increase the anticoagulant activities of Protein C.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Protein C.Experimental
Ferulic acidFerulic acid may increase the anticoagulant activities of Protein C.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Protein C.Investigational
FloctafenineFloctafenine may increase the anticoagulant activities of Protein C.Approved, Withdrawn
FluindioneProtein C may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Protein C.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Protein C.Experimental
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Protein C.Approved, Investigational
FondaparinuxProtein C may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Protein C.Approved, Investigational
GabexateProtein C may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Protein C.Investigational
GestodeneThe therapeutic efficacy of Protein C can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Protein C can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Protein C can be decreased when used in combination with Gestrinone.Approved
GuacetisalGuacetisal may increase the anticoagulant activities of Protein C.Experimental
HeminHemin may increase the anticoagulant activities of Protein C.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Protein C.Experimental
HeparinHeparin may increase the anticoagulant activities of Protein C.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Protein C.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Protein C.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Protein C can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Protein C.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Protein C is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Protein C.Approved
IbudilastIbudilast may increase the anticoagulant activities of Protein C.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Protein C.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Protein C.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Protein C.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Protein C.Approved, Investigational, Nutraceutical
IdraparinuxIdraparinux may increase the anticoagulant activities of Protein C.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Protein C.Investigational
IloprostIloprost may increase the anticoagulant activities of Protein C.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Protein C.Experimental
IndobufenIndobufen may increase the anticoagulant activities of Protein C.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Protein C.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Protein C.Withdrawn
IsoxicamIsoxicam may increase the anticoagulant activities of Protein C.Withdrawn
KebuzoneKebuzone may increase the anticoagulant activities of Protein C.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Protein C.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Protein C.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Protein C.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Protein C.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Protein C.Approved
LetaxabanProtein C may increase the anticoagulant activities of Letaxaban.Investigational
LevonorgestrelThe therapeutic efficacy of Protein C can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Protein C.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Protein C.Experimental
LisofyllineLisofylline may increase the anticoagulant activities of Protein C.Investigational
LonazolacLonazolac may increase the anticoagulant activities of Protein C.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Protein C.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Protein C.Approved, Investigational
LumiracoxibLumiracoxib may increase the anticoagulant activities of Protein C.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Protein C.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Protein C.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Protein C.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Protein C can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Protein C can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Protein C.Approved
Megestrol acetateThe therapeutic efficacy of Protein C can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranProtein C may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamMeloxicam may increase the anticoagulant activities of Protein C.Approved, Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Protein C.Approved
MestranolMestranol may decrease the anticoagulant activities of Protein C.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Protein C.Experimental
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Protein C.Approved, Vet Approved
MethylestrenoloneThe therapeutic efficacy of Protein C can be decreased when used in combination with Methylestrenolone.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Protein C.Approved
MizoribineMizoribine may increase the anticoagulant activities of Protein C.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Protein C.Experimental
MoxestrolMoxestrol may decrease the anticoagulant activities of Protein C.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Protein C.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Protein C.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Protein C.Approved
NadroparinNadroparin may increase the anticoagulant activities of Protein C.Approved, Investigational
NafamostatNafamostat may increase the anticoagulant activities of Protein C.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Protein C.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Protein C.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Protein C.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Protein C.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Protein C.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Protein C.Approved
NimesulideNimesulide may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Protein C is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Protein C.Investigational
NomegestrolThe therapeutic efficacy of Protein C can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Protein C can be decreased when used in combination with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Protein C can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Protein C is combined with Obinutuzumab.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Protein C.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Protein C.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Protein C is combined with Omacetaxine mepesuccinate.Approved, Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Protein C.Approved, Nutraceutical
OrgoteinOrgotein may increase the anticoagulant activities of Protein C.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Protein C.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Protein C.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Protein C.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Protein C.Investigational
ParecoxibParecoxib may increase the anticoagulant activities of Protein C.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Protein C.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Protein C.Approved, Investigational
Pentaerythritol TetranitratePentaerythritol Tetranitrate may increase the anticoagulant activities of Protein C.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Protein C.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Protein C.Approved, Investigational
PhenindionePhenindione may increase the anticoagulant activities of Protein C.Approved, Investigational
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Protein C.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Protein C.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Protein C.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Protein C.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Protein C.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Protein C.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Protein C.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Protein C.Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Protein C.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Protein C.Approved
ProgesteroneThe therapeutic efficacy of Protein C can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Protein C.Experimental
PromegestoneThe therapeutic efficacy of Protein C can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Protein C.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Protein C.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Protein C.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Protein C.Experimental
Protein S humanProtein C may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeProtocatechualdehyde may increase the anticoagulant activities of Protein C.Approved
PTC299PTC299 may increase the anticoagulant activities of Protein C.Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Protein C.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Protein C.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Protein C.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Protein C.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Protein C.Approved, Investigational
ReviparinReviparin may increase the anticoagulant activities of Protein C.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Protein C.Approved
RivaroxabanProtein C may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Protein C.Approved, Investigational
SalicylamideSalicylamide may increase the anticoagulant activities of Protein C.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Protein C.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Protein C.Approved
SarpogrelateSarpogrelate may increase the anticoagulant activities of Protein C.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Protein C.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Protein C.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Protein C.Approved
SemapimodSemapimod may increase the anticoagulant activities of Protein C.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Protein C.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Protein C.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Protein C.Approved, Vet Approved
SRT501SRT501 may increase the anticoagulant activities of Protein C.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Protein C.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Protein C.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Protein C.Approved
SulindacSulindac may increase the anticoagulant activities of Protein C.Approved, Investigational
SulodexideSulodexide may increase the anticoagulant activities of Protein C.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Protein C.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Protein C.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Protein C.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Protein C.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Protein C.Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Protein C.Approved
TenidapTenidap may increase the anticoagulant activities of Protein C.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Protein C.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Protein C.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Protein C.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Protein C.Investigational
Testosterone cypionateThe therapeutic efficacy of Protein C can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Protein C can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Protein C can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Protein C.Approved
TiboloneTibolone may increase the anticoagulant activities of Protein C.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Protein C.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Protein C.Approved
TinoridineTinoridine may increase the anticoagulant activities of Protein C.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Protein C.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Protein C.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Protein C.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Protein C.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Protein C.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Protein C.Approved
TositumomabThe risk or severity of adverse effects can be increased when Protein C is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Protein C.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Protein C.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Protein C.Approved, Investigational
TribenosideTribenoside may increase the anticoagulant activities of Protein C.Experimental
TriflusalTriflusal may increase the anticoagulant activities of Protein C.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Protein C.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Protein C.Approved
TroxerutinProtein C may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the anticoagulant activities of Protein C.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Protein C.Approved
WarfarinWarfarin may increase the anticoagulant activities of Protein C.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Protein C.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Protein C.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Protein C.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Protein C.Withdrawn
Food Interactions
Not Available

References

General References
  1. Esmon CT, Vigano-D'Angelo S, D'Angelo A, Comp PC: Anticoagulation proteins C and S. Adv Exp Med Biol. 1987;214:47-54. [PubMed:2959034]
External Links
KEGG Drug
D08796
PubChem Substance
347911185
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Protein_C
ATC Codes
B01AD12 — Protein c
FDA label
Download (674 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentThrombosis1
3CompletedTreatmentAcute Major Bleeding / Disorders, Blood Coagulation1
3CompletedTreatmentReversal of Anticoagulant Treatment1
3CompletedTreatmentReversal of Coagulopathy1
3Not Yet RecruitingTreatmentHeart Disease End Stage / Heart Failureļ¼ŒCongestive1
3RecruitingTreatmentSignificant Bleeding Risk1
3TerminatedTreatmentSepsis1
4Enrolling by InvitationTreatmentBlood Loss,Surgical / Cardiovascular Surgical Procedures / Fresh Frozen Plasma / Haemorrhage / Prothrombin Complex Concentrates1
4Unknown StatusTreatmentPostpartum Hemorrhage1
Not AvailableCompletedNot AvailableHemorrhage1
Not AvailableCompletedNot AvailableHypercoagulability / Severe Congenital Protein C Deficiency1
Not AvailableRecruitingNot AvailableHemorrhage1
Not AvailableWithdrawnTreatmentIntracranial Hemorrhage, Spontaneous / Intracranial Hemorrhage, Traumatic1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous
Injection, powder, for solutionIntravenous1000 IU
Injection, powder, for solutionIntravenous500 IU
Kit
Kit
Kit; powder, for solutionIntravenous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on December 03, 2015 09:52 / Updated on February 03, 2018 14:02